Leavitt Partners creates panel of health IT leaders

Leavitt Partners has created FuturePanel, a group of healthcare thought leaders to inform, refine and guide the healthcare intelligence shared by the Salt Lake City-based firm.

FuturePanel members include former senior executives from the Centers for Medicare & Medicaid Services (CMS), U.S. leaders in health IT, veterans of state-level healthcare policy, clinical experts and economic and legal professionals.

“FuturePanel provides our clients with a cross-disciplinary view of healthcare intelligence and enables them to make strategic planning decisions based on the available information,” according to a statement released by the firm. Members of FuturePanel inform the healthcare intelligence of Leavitt Partners through consultations, interdisciplinary conference calls and quarterly briefings.

FuturePanel members include the following:
  • Michael O. Leavitt, chairman, former secretary of Department of Health and Human Services (HHS);
  • Joel Ario, former director of the Office of Insurance Exchanges, HHS, and Pennsylvania Insurance Commissioner;
  • Robin Arnold-Williams, former executive policy director, Washington State Governor’s Office;
  • Thomas Barker, former acting general counsel for HHS;
  • David Blumenthal, MD, former national coordinator for health IT and current professor of medicine and healthcare policy at Massachusetts General Hospital and Harvard Medical School in Boston;
  • Charlene Frizzera, former acting administrator for CMS;
  • James Madara, MD, executive vice president and CEO of the American Medical Association (AMA);
  • Karen Milgate, former deputy director of the Center for Strategic Planning at CMS;
  • John Nelson, MD, past president of the AMA and Leavitt Partners chief medical officer;
  • Ray Scheppach, former executive director of the National Governors Association;
  • Barry Straube, MD, former chief medical officer for CMS;
  • Vince Ventimiglia, former assistant secretary for legislation, HHS;
  • Ronald Williams, former chairman and CEO of Aetna; and
  • Susan Winckler, former chief of staff for the FDA.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.